
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.131
vdae090.131
Final Category: Translational Science
AcademicSubjects/MED00300
AcademicSubjects/MED00310
TRSC-02 RESPONSE TO PARP INHIBITORS IN PATIENTS WITH BREAST CANCER METASTATIC TO THE CENTRAL NERVOUS SYSTEM
Grinda Thomas Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Gustave Roussy, Medical Oncology Department, Villejuif, France

Lee Seoho Johns Hopkins University School of Medicine, Baltimore, MD, USA

Bansal Rani Duke Cancer Institute, Durham, NC, USA

Hughes Melissa Dana-Farber Cancer Institute, Boston, MA, USA

Swearingen Amanda Van Duke Cancer Institute, Durham, NC, USA

Moore Heather Duke Cancer Institute, Durham, NC, USA

Kamson David Johns Hopkins University School of Medicine, Baltimore, MD, USA

Sahebjam Solmaz Johns Hopkins University School of Medicine, Baltimore, MD, USA

Kirkner Greg Dana-Farber Cancer Institute, Boston, MA, USA

Gorfinkel Anna Dana-Farber Cancer Institute, Boston, MA, USA

Sammons Sarah Dana-Farber Cancer Institute, Boston, MA, USA

Lin Nancy Dana-Farber Cancer Institute, Boston, MA, USA

Anders Carey Duke Cancer Institute, Durham, NC, USA

Santa-Maria Cesar Johns Hopkins University School of Medicine, Baltimore, MD, USA

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i40i40
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

BACKGROUND

Central nervous system (CNS) metastasis from breast cancer can be challenging to treat due to the limited blood brain barrier penetration of many systemic therapies. The goal of our study is to describe the clinical benefit of PARP inhibitors (PARPi) in patients with breast cancer CNS metastasis.

METHODS

This retrospective case series was conducted at three academic cancer centers (Johns Hopkins, Dana-Farber, and Duke) and included patients with the following criteria: age≥18 years with a breast cancer diagnosis (any subtype); diagnosis of parenchymal brain metastasis or leptomeningeal disease (LMD); and received PARPi for CNS metastasis. Descriptive statistics, Kruskal-Wallis rank sum tests, and Kaplan-Meier analyses were performed.

RESULTS

Although this analysis includes one center’s experience, we will present a combined dataset (N = 45) at the main conference. 11 patients were identified at Johns Hopkins. 4 (36.4%) were Black and 6 (54.5%) were White; 6 (54.5%) had ER+HER2- disease and 5 (45.5%) had TNBC; 5 (45.5%) had BRCA1 mutations and 5 (45.5%) had BRCA2 mutations. Median lines of therapy prior to PARPi was 6 [1 - 11]. On average, patients remained on PARPi for 5 months [0.5 - 66], and overall survival (OS) time from PARPi to death was 16 months [2 - 66]. Duration of PARPi and OS did not differ significantly between ER+HER2- and TNBC (p=0.74 and 0.69) or BRCA 1 and 2 (p=0.78 and 0.72). Black patients had significantly shorter PARPi duration and survival than White patients (PARPi 2 vs. 8 months, p=0.028 and OS 4 vs 18 months, p=0.028). Prior CNS radiation was significantly associated with longer PARPi duration and survival (PARPi 5 vs 1 month, p=0.02 and OS 17 vs. 3 months, p=0.032).

CONCLUSIONS

PARPi are associated with significant clinical benefit in patients with breast cancer CNS metastasis. Larger data series will help confirm these observations.
==== Body
pmc
